Humacyte (HUMA) Income towards Parent Company (2020 - 2026)

Humacyte (HUMA) has reported Income towards Parent Company for 7 consecutive years, with -$30.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 20.77% year-over-year to -$30.8 million; the TTM figure through Mar 2026 stood at -$179.2 million (down 52.74% YoY), while the FY2025 annual figure was -$116.8 million, up 60.16% from the prior year.
• Income towards Parent Company was little changed at -$30.8 million in Q1 2026 per HUMA's latest filing, from -$30.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$19.7 million in Q2 2022 and bottomed at -$86.0 million in Q3 2025.
• Historically, Income towards Parent Company has averaged -$30.8 million across 5 years, with a median of -$29.3 million in 2024.
• Annual changes were most pronounced in 2023 — Income towards Parent Company climbed 23.74% — and 2025, when it tumbled 170.83%.
• Humacyte's Income towards Parent Company stood at -$21.0 million in 2022, then sank by 42.58% to -$30.0 million in 2023, then gained by 2.14% to -$29.3 million in 2024, then slipped by 5.4% to -$30.9 million in 2025, then climbed by 0.26% to -$30.8 million in 2026.
• Business Quant data shows HUMA's Income towards Parent Company at -$30.8 million in Q1 2026, -$30.9 million in Q4 2025, and -$86.0 million in Q3 2025.